

November 24, 2021



## GT BioPharma to Host a Management Update Conference Call

**- Tuesday, November 30th at 4:30PM Eastern Time**

BEVERLY HILLS, Calif., Nov. 24, 2021 /PRNewswire/ -- GT Biopharma, Inc. (the "Company") (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager, TriKE® platform, today announced that Michael Breen, Executive Chairman and Dr. Greg Berk, President of R&D, Chief Medical Officer and Interim Chief Executive Officer will be hosting a Management Update Conference call on Tuesday, November 30<sup>th</sup> at 4:30PM Eastern Time.



To join the live webcast of the call and view the accompanying slide presentation, please use this link:

[https://viaavid.webcasts.com/starthere.jsp?ei=1516135&tp\\_key=68a3021ba2](https://viaavid.webcasts.com/starthere.jsp?ei=1516135&tp_key=68a3021ba2)

Those who wish to dial in by phone for the audio portion only of the event may do so at:

PARTICIPANT TOLL FREE DIAL-IN: 1-877-407-9039

PARTICIPANT INTERNATIONAL DIAL-IN: 1-201-689-8470

CONFERENCE ID: 13725380

An archived replay of the webcast will be available on the Company's website by visiting: <https://www.gtbiopharma.com/news-media/presentations>

## **About GT Biopharma, Inc.**

GT Biopharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of immuno-oncology therapeutic products based on our proprietary TriKE® NK cell engager platform. Our TriKE® platform is designed to harness and enhance the cancer killing abilities of a patient's immune system's natural killer cells. GT Biopharma has an exclusive worldwide license agreement with the University of Minnesota to further develop and commercialize therapies using TriKE® technology. For more information, please visit [gtbiopharma.com](http://gtbiopharma.com).

## **Forward-Looking Statements**

The Management Update Conference Call will contain certain forward-looking statements that involve risks, uncertainties and assumptions that are difficult to predict, including statements regarding our clinical focus, and our current and proposed trials. Words and expressions reflecting optimism, satisfaction or disappointment with current prospects, as well as words such as "believes", "hopes", "intends", "estimates", "expects", "projects", "plans", "anticipates" and variations thereof, or the use of future tense, identify forward-looking statements, but their absence does not mean that a statement is not forward-looking. Our forward-looking statements are not a guarantee of performance, and actual results could differ materially from those contained in or expressed by such statements. In evaluating all such statements, we urge you to specifically consider the various risk factors identified in our Annual Report on Form 10-K for the year ended December 31, 2020, our subsequent current reports on Form 8-K, our Quarterly Report on Form 10-Q for the quarter ended September 30, 2021, and our other filings with the Securities and Exchange Commission, any of which could cause actual results to differ materially from those indicated by our forward-looking statements.

Our forward-looking statements reflect our current views with respect to future events and are based on currently available financial, economic, scientific, and competitive data and information on current business plans. You should not place undue reliance on our forward-looking statements, which are subject to risks and uncertainties relating to, among other things: (i) the sufficiency of our cash position and our ongoing ability to raise additional capital to fund our operations, (ii) our ability to complete our contemplated clinical trials, or to meet the FDA's requirements with respect to safety and efficacy, (iii) our ability to identify patients to enroll in our clinical trials in a timely fashion, (iv) our ability to achieve approval of a marketable product, (v) design, implementation and conduct of clinical trials, (vi) the results of our clinical trials, including the possibility of unfavorable clinical trial results, (vii) the market for, and marketability of, any product that is approved, (viii) the existence or development of treatments that are viewed by medical professionals or patients as superior to our products, (ix) regulatory initiatives, compliance with governmental regulations and the regulatory approval process, and social conditions, and (x) various other matters, many of which are beyond our control. Should one or more of these risks or uncertainties develop, or should underlying assumptions prove to be incorrect, actual results may vary materially and adversely from those anticipated, believed, estimated, or otherwise indicated by our forward-looking statements.

We intend that all forward-looking statements made in Management Update Call will be subject to the safe harbor protection of the federal securities laws pursuant to Section 27A of the Securities Act, to the extent applicable. Except as required by law, we do not undertake any responsibility to update these forward-looking statements to take into account events or circumstances that occur after the date of the Management Update Call. Additionally, we do not undertake any responsibility to update you on the occurrence of any unanticipated events which may cause actual results to differ from those expressed or implied by these forward-looking statements.

TriKE is a registered trademark owned by GT Biopharma, Inc.

### **Investor Relations Contacts:**

#### **GT Biopharma-Investor Relations Consultant**

David Castaneda

[David@gtbiopharma.com](mailto:David@gtbiopharma.com)

414-351-9758

#### **LifeSci Advisors**

Corey Davis, Ph.D.

[cdavis@lifesciadvisors.com](mailto:cdavis@lifesciadvisors.com)

212-915-2577

🔗 View original content to download multimedia <https://www.prnewswire.com/news-releases/gt-biopharma-to-host-a-management-update-conference-call-301431776.html>

SOURCE GT Biopharma, Inc.